# NALIRIFOX as Induction Therapy in LAPC

> **NCT06467565** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 20 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Liposomal irinotecan

## Key facts

- **NCT ID:** NCT06467565
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-25
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06467565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06467565, "NALIRIFOX as Induction Therapy in LAPC". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06467565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*